Nxera Pharma Co Ltd (FRA:JSS)
€ 8.75 -0.3 (-3.31%) Market Cap: 793.19 Mil Enterprise Value: 946.53 Mil PE Ratio: 0 PB Ratio: 2.12 GF Score: 66/100

Sosei Group Corp at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 02:00PM GMT
Release Date Price: €12.9
Chris Cargill
Sosei Group Corporation - Executive Officer & CFO

Good morning. My name is Chris Cargill, Chief Financial Officer at Sosei Group Corporation. Today, I will give you a brief overview of our technology, platform, core capabilities, business model, pipeline programs and an insight into our strategy.

Please turn to Slide 3. Now firstly, a quick introduction for those that are new to our company. We are a world-leading team of drug hunters, and we're specifically focused on G protein-coupled receptors or GPCRs. We apply a proprietary technology called StaR, which stands for Stabilized Receptor, and leverage our structure-based drug design platform infrastructure to discover novel and best-in-class small molecule therapeutics.

We are an Anglo-Japanese company, publicly listed in Japan. However, our main R&D campus is located in Cambridge, U.K., and this is where 80% of our R&D employees are based. Our ambition is to become one of Japan's global biotechnology and drug discovery champions.

We are a science-led organization. Over 75% of our staff have a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot